Literature DB >> 16192644

Isolation and growth of smooth muscle-like cells derived from tuberous sclerosis complex-2 human renal angiomyolipoma: epidermal growth factor is the required growth factor.

Elena Lesma1, Vera Grande, Stephana Carelli, Diego Brancaccio, Maria Paola Canevini, Rosa Maria Alfano, Guido Coggi, Anna Maria Di Giulio, Alfredo Gorio.   

Abstract

Tuberous sclerosis complex (TSC) is a tumor suppressor gene disorder characterized by mutations in the TSC1 or TSC2 genes. These mutations lead to the development of benign tumors involving smooth muscle cells, causing life-threatening lymphangioleiomyomatosis. We isolated and characterized two types of cells bearing a mutation in TSC2 exon 18 from a renal angiomyolipoma of a TSC patient: one population of alpha-actin-positive smooth muscle-like cells with loss of heterozygosity for the TSC2 gene (A(+) cells) and another of nonloss of heterozygosity keratin 8/18-positive epithelial-like cells (R(+) cells). Unlike control aortic vascular smooth muscle cells, A(+) cells required epidermal growth factor (EGF) to grow and substituting EGF with insulin-like growth factor (IGF)-1 failed to increase the cell number; however, omission of EGF did not cause cell loss. The A(+) cells constantly released IGF-1 into the culture medium and constitutively showed a high degree of S6K phosphorylation even when grown in serum-free medium. Exposure to antibodies against EGF and IGF-1 receptors caused a rapid loss of A(+) cells: 50% by 5 days and 100% by 12 days. Signal transduction mediated by EGF and IGF-I receptors is therefore involved in A(+) cell survival. These results may offer a novel therapeutic perspective for the treatment of TSC complications and lymphangioleiomyomatosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16192644      PMCID: PMC1603666          DOI: 10.1016/S0002-9440(10)61198-4

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  43 in total

1.  Interaction between hamartin and tuberin, the TSC1 and TSC2 gene products.

Authors:  M van Slegtenhorst; M Nellist; B Nagelkerken; J Cheadle; R Snell; A van den Ouweland; A Reuser; J Sampson; D Halley; P van der Sluijs
Journal:  Hum Mol Genet       Date:  1998-06       Impact factor: 6.150

2.  Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis.

Authors:  T Carsillo; A Astrinidis; E P Henske
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-23       Impact factor: 11.205

3.  The TSC1 tumour suppressor hamartin regulates cell adhesion through ERM proteins and the GTPase Rho.

Authors:  R F Lamb; C Roy; T J Diefenbach; H V Vinters; M W Johnson; D G Jay; A Hall
Journal:  Nat Cell Biol       Date:  2000-05       Impact factor: 28.824

4.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

Review 5.  Metastasis of benign tumor cells in tuberous sclerosis complex.

Authors:  Elizabeth Petri Henske
Journal:  Genes Chromosomes Cancer       Date:  2003-12       Impact factor: 5.006

6.  Mutation and cancer: statistical study of retinoblastoma.

Authors:  A G Knudson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-04       Impact factor: 11.205

7.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

8.  Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways.

Authors:  Jane Yu; Aristotelis Astrinidis; Sharon Howard; Elizabeth Petri Henske
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2003-08-15       Impact factor: 5.464

9.  Angiomyolipoma of the kidney. Immunoreactivity with HMB-45. Light- and electron-microscopic findings.

Authors:  E Kaiserling; S Kröber; J C Xiao; G Schaumburg-Lever
Journal:  Histopathology       Date:  1994-07       Impact factor: 5.087

10.  TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase.

Authors:  Elena Goncharova; Dmitry Goncharov; Daniel Noonan; Vera P Krymskaya
Journal:  J Cell Biol       Date:  2004-12-20       Impact factor: 10.539

View more
  20 in total

1.  Lymphangioleiomyomatosis--presence of receptor tyrosine kinases and the angiogenesis factor VEGF-A as potential therapeutic targets.

Authors:  Henrik Watz; Knut Engels; Siegfried Loeschke; Michael Amthor; Detlef Kirsten; Helgo Magnussen
Journal:  Thorax       Date:  2007-06       Impact factor: 9.139

Review 2.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 3.  Lymphangioleiomyomatosis and TSC2-/- cells.

Authors:  Thomas N Darling; Gustavo Pacheco-Rodriguez; Alfredo Gorio; Elena Lesma; Cheryl Walker; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

4.  BMP-gated cell-cycle progression drives anoikis during mesenchymal collective migration.

Authors:  Frank Macabenta; Hsuan-Te Sun; Angelike Stathopoulos
Journal:  Dev Cell       Date:  2022-06-15       Impact factor: 13.417

5.  The methylation of the TSC2 promoter underlies the abnormal growth of TSC2 angiomyolipoma-derived smooth muscle cells.

Authors:  Elena Lesma; Silvia Maria Sirchia; Silvia Ancona; Stephana Carelli; Silvano Bosari; Filippo Ghelma; Emanuele Montanari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Am J Pathol       Date:  2009-05-14       Impact factor: 4.307

6.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

7.  Survivin expression in tuberous sclerosis complex cells.

Authors:  Stephana Carelli; Elena Lesma; Simona Paratore; Vera Grande; Giorgia Zadra; Silvano Bosari; Anna Maria Di Giulio; Alfredo Gorio
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

8.  Detection of low-prevalence somatic TSC2 mutations in sporadic pulmonary lymphangioleiomyomatosis tissues by deep sequencing.

Authors:  Atsushi Fujita; Katsutoshi Ando; Etsuko Kobayashi; Keiko Mitani; Koji Okudera; Mitsuko Nakashima; Satoko Miyatake; Yoshinori Tsurusaki; Hirotomo Saitsu; Kuniaki Seyama; Noriko Miyake; Naomichi Matsumoto
Journal:  Hum Genet       Date:  2015-11-12       Impact factor: 4.132

9.  Mesenchymal Tumorigenesis Driven by TSC2 Haploinsufficiency Requires HMGA2 and Is Independent of mTOR Pathway Activation.

Authors:  Jeanine D'Armiento; Takayuki Shiomi; Sarah Marks; Patrick Geraghty; Devipriya Sankarasharma; Kiran Chada
Journal:  Cancer Res       Date:  2016-02-02       Impact factor: 12.701

10.  Real-time monitoring of tumorigenesis, dissemination, & drug response in a preclinical model of lymphangioleiomyomatosis/tuberous sclerosis complex.

Authors:  Fangbing Liu; Elaine P Lunsford; Jingli Tong; Yoshitomo Ashitate; Summer L Gibbs; Jane Yu; Hak Soo Choi; Elizabeth P Henske; John V Frangioni
Journal:  PLoS One       Date:  2012-06-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.